Analysts predict that Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) will post earnings of ($0.04) per share for the current quarter, according to Zacks. Four analysts have made estimates for Pacira Pharmaceuticals’ earnings. The highest EPS estimate is $0.10 and the lowest is ($0.16). Pacira Pharmaceuticals reported earnings per share of $0.20 during the same quarter last year, which suggests a negative year over year growth rate of 120%. The company is expected to issue its next quarterly earnings report before the market opens on Wednesday, November 8th.

On average, analysts expect that Pacira Pharmaceuticals will report full-year earnings of ($0.17) per share for the current year, with EPS estimates ranging from ($0.42) to $0.16. For the next financial year, analysts expect that the company will post earnings of $0.90 per share, with EPS estimates ranging from $0.14 to $1.60. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Pacira Pharmaceuticals.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings data on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.06). The firm had revenue of $70.90 million for the quarter, compared to the consensus estimate of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.21 EPS.

A number of analysts recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $87.00 price objective on shares of Pacira Pharmaceuticals in a report on Wednesday, August 23rd. Mizuho restated a “buy” rating and issued a $54.00 target price on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. Piper Jaffray Companies restated a “buy” rating and issued a $55.00 target price on shares of Pacira Pharmaceuticals in a research note on Friday, October 27th. ValuEngine lowered Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Finally, BidaskClub lowered Pacira Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $50.43.

In other Pacira Pharmaceuticals news, Director Paul J. Hastings sold 1,044 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $36.15, for a total transaction of $37,740.60. Following the sale, the director now directly owns 3,518 shares of the company’s stock, valued at $127,175.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kristen Marie Williams sold 3,461 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total value of $127,191.75. Following the sale, the chief accounting officer now directly owns 21,312 shares in the company, valued at $783,216. The disclosure for this sale can be found here. Insiders have sold 33,390 shares of company stock worth $1,215,480 over the last three months. 6.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PCRX. Oppenheimer Asset Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the second quarter valued at approximately $114,000. Benjamin F. Edwards & Company Inc. lifted its holdings in Pacira Pharmaceuticals by 12.2% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 2,794 shares of the company’s stock worth $133,000 after buying an additional 303 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in Pacira Pharmaceuticals by 121.5% during the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after buying an additional 1,752 shares during the period. QS Investors LLC purchased a new stake in Pacira Pharmaceuticals during the second quarter worth $157,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in Pacira Pharmaceuticals by 9.6% during the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after buying an additional 302 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece was published by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/pacira-pharmaceuticals-inc-pcrx-expected-to-announce-earnings-of-0-04-per-share/1674343.html.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Get a free copy of the Zacks research report on Pacira Pharmaceuticals (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.